Help Transform Recovery1‑3
Jump to
Jump to
ACQUIRING SUBLOCADE® FOR YOUR PRACTICE
There are 2 ways to acquire SUBLOCADE for your practice: through a specialty pharmacy or a specialty distributor.
Specialty Pharmacy
Steps to acquire SUBLOCADE through a specialty pharmacy
Process Overview
INSUPPORT can provide an overview of the patient's benefit coverage for SUBLOCADE. Patient benefit coverage information can be provided for the current site of care, or for a new treatment provider if the patient is transitioning to a new healthcare setting.
It is important to understand that INSUPPORT does not determine coverage and provides benefit information as it is reported by the patient's insurance provider.
Enrolling the patient in INSUPPORT
For patients who enroll in "Benefit Coverage Information" through INSUPPORT, INSUPPORT can conduct a benefit investigation of the patient's insurance coverage for SUBLOCADE for the patient's current site of care. INSUPPORT can also provide information on the prior authorization and/or appeals requirements and confirm product acquisitions from the patient's insurance provider.
Get started, select a tab below to view steps for your preferred method of enrollment.
What is the INSUPPORT Portal?
The INSUPPORT Portal allows healthcare providers (HCPs) to electronically enroll patients in any program option offered by INSUPPORT. It also allows for Patient Authorization to be requested, completed, and submitted by the patient to INSUPPORT via electronic signature.
Once on the portal, 1) select a product, 2) select "healthcare provider" as the user type, 3) enter the required HCP information, and 4) indicate the requested program option(s) for your patient. No registration is required to use the portal.
GO TO INSUPPORTPORTAL.COM
Once you have selected the requested program option(s) for the patient, you must complete the required information fields in the enrollment form, including your electronic signature and date for the Provider Attestation. You will then be able to initiate a request via email to the patient for him/her to complete the Patient Authorization via electronic signature and submit it to INSUPPORT. Once the Patient Authorization is received from the patient, INSUPPORT will begin to process the enrollment request.
If you require assistance in other languages, please call INSUPPORT at 1‑844‑INSPPRT (1‑844‑467‑7778).
Review benefits and next steps
For patients enrolled in "Benefit Coverage Information," INSUPPORT will provide a Final Benefit Summary to the patient and healthcare provider (HCP) office, detailing the outcome of the benefit investigation. The document outlines the patient's benefit coverage information for SUBLOCADE and, if applicable, the patient's enrollment status in the SUBLOCADE Copay Assistance Program. It will also indicate whether a prior authorization (PA) is required from a patient's insurance provider for a final coverage determination.
View an Annotated Sample Final Benefit Summary from INSUPPORT†
Sample form
†This annotated sample is intended for informational purposes only and not for direct use as a benefits summary.
If you requested for INSUPPORT to route your patient's information to a specialty pharmacy on the Enrollment Form, you will need to send the patient's SUBLOCADE prescription to the specialty pharmacy identified in the "Prescription Routing Information" section of the Final Benefit Summary in order to initiate the specialty pharmacy process.
If you did not request for INSUPPORT to route patient's information, INSUPPORT will notify you of any mandated or preferred network specialty pharmacies reported by the patient's insurance provider in the "Specialty Pharmacy Information" section of the Final Benefit Summary.
Going directly to a specialty pharmacy?
Specialty pharmacies verify benefits using their own process before dispensing a product to a patient, regardless of if benefits have been investigated by INSUPPORT.
For HCPs who choose to refer patients directly to a specialty pharmacy, an intake form will need to be completed for the chosen network specialty pharmacy. The completed intake form may require signature(s) along with a valid prescription that must be faxed or e‑prescribed to the specialty pharmacy to start the process.
INSUPPORT can provide the contact information for network specialty pharmacies.
Completing your own benefit investigation
Your office can choose to contact the patient's health insurance provider to conduct a benefit investigation yourself.
INSUPPORT can provide information on PAs and/or requirements and processes.
Completing a PA
Some insurance providers may require a PA to grant a patient coverage for SUBLOCADE® (buprenorphine extended-release) injection, for subcutaneous use, CIII.
INSUPPORT can provide information on the PA process and/or PA requirements from a patient's insurance provider, when applicable. Regardless of whether patient information is provided from INSUPPORT or directly from a healthcare provider (HCP) office, the specialty pharmacy receiving the patient's prescription will verify the patient's benefits as part of their benefit investigation process, and will provide the insurance provider's PA requirements and/or forms to the HCP office, if applicable.
Is a PA required?
When a PA is required by the patient's insurance provider, the specialty pharmacy will contact the HCP office regarding the authorization submission process and required information.
The patient's healthcare provider must complete and submit the PA form(s) to the patient's insurance provider.
Once the required PA forms are submitted to the patient's insurance provider, the specialty pharmacy will check the status of the PA request until an outcome is determined by the patient's insurance provider.
Once a coverage determination has been made, the patient's insurance provider will communicate the outcome of the PA request to the HCP office. The HCP may review the outcome to inform next steps.
For eligible patients,* the SUBLOCADE Copay Assistance Program may be able to help with out-of-pocket costs for SUBLOCADE.
Submit the patient's prescription for SUBLOCADE to a network specialty pharmacy.
Once the specialty pharmacy has verified the patient's benefit coverage and received a valid prescription for SUBLOCADE, the specialty pharmacy will work with the office staff to coordinate shipment of SUBLOCADE in conjunction with the patient's appointment.
Once SUBLOCADE is acquired, store the medication according to regulatory and labeling requirements.
SUBLOCADE is a federal Class III controlled substance and requires special handling and storage.
Information on proper storage requirements can be found in the Prescribing Information for SUBLOCADE.
There may be other storage requirements not addressed in the Prescribing Information; refer to state and federal regulations.
Following the administration of SUBLOCADE to the patient, your practice is responsible for submitting a claim to the patient's insurance provider for administration of the medication.
Medical Services Reimbursement
Specialty pharmacies are responsible for billing the insurance provider for the cost of SUBLOCADE. The healthcare provider (HCP) office should only submit a claim to the insurance provider for the medical services.
Following administration of SUBLOCADE to the patient, submit a claim to the patient's insurance provider. Here is billing and coding information.
If the claim is approved, the patient's insurance provider should make the payment to the HCP office.
Addressing claim denials
If your claim is denied by the patient's insurance provider, you will be notified of the denial reason by the insurance provider.
Some of the common reasons for denial include:
- Incomplete or inaccurate information
- Lack of prior authorization
- Diagnosis and procedure coding errors and omissions
- Insufficient medical necessity
Buy & Bill
Steps to acquire SUBLOCADE through a specialty distributor
Process Overview
INSUPPORT can provide an overview of the patient's benefit coverage for SUBLOCADE. Patient benefit coverage information can be provided for the current site of care, or for a new treatment provider if the patient is transitioning to a new healthcare setting.
It is important to understand that INSUPPORT does not determine coverage and provides benefit information as it is reported by the patient's insurance provider.
Enrolling the patient in INSUPPORT
For patients who enroll in "Benefit Coverage Information" through INSUPPORT, INSUPPORT can conduct a benefit investigation of the patient's insurance coverage for SUBLOCADE for the patient's current site of care. INSUPPORT can also provide information on the prior authorization and/or appeals requirements and confirm product acquisitions from the patient's insurance provider.
Get started: select a tab below to view steps for your preferred method of enrollment.
What is the INSUPPORT Portal?
The INSUPPORT Portal allows healthcare providers (HCPs) to electronically enroll patients in any program option offered by INSUPPORT. It also allows for Patient Authorization to be requested, completed, and submitted by the patient to INSUPPORT via electronic signature.
Once on the portal, 1) select a product, 2) select "healthcare provider" as the user type, 3) enter the required HCP information, and 4) indicate the requested program option(s) for your patient. No registration is required to use the portal.
GO TO INSUPPORTPORTAL.COMOnce you have selected the requested program option(s) for the patient, you must complete the required information fields in the enrollment form, including your electronic signature and date for the Provider Attestation. You will then be able to initiate a request via email to the patient for him/her to complete the Patient Authorization via electronic signature and submit it to INSUPPORT. Once the Patient Authorization is received from the patient, INSUPPORT will begin to process the enrollment request.
If you require assistance in other languages, please call INSUPPORT at 1‑844‑INSPPRT (1‑844‑467‑7778).
Completing your own benefit investigation
You or your office staff can choose to conduct a benefit investigation yourself.
INSUPPORT can provide information on PAs and/or appeal requirements and processes. If applicable, INSUPPORT can provide payer-specific PA forms that the healthcare provider (HCP) office will need to complete and submit to the patient's insurance provider.
Completing a PA
Some insurance providers may require a PA to grant a patient coverage for SUBLOCADE® (buprenorphine extended-release) injection, for subcutaneous use, CIII.
INSUPPORT can provide information on the PA process and/or PA requirements from a patient's insurance provider, when applicable.
Is a PA required?
When applicable, INSUPPORT can provide insurer PA requirements to a healthcare provider (HCP) office. The patient's HCP must complete and submit any required PA form(s) to the patient's insurance provider.
Once the required PA forms and/or documentation are submitted to the patient's insurance provider, INSUPPORT can check the status of the PA request until an outcome is determined by the patient's insurance provider.
Once a coverage determination has been made, the patient's insurance provider will communicate the outcome of the PA request, and INSUPPORT will follow up with the HCP office on next steps or with the Final Benefit Summary.
For eligible patients,* the SUBLOCADE Copay Assistance Program may be able to help with out‑of‑pocket costs for SUBLOCADE.
Order SUBLOCADE from a specialty distributor. To acquire SUBLOCADE, you must set up an account with a .
To acquire SUBLOCADE, you must set up an account with a network specialty distributor. SUBLOCADE is only available through .
Many specialty distributors offer online, email, and phone ordering.
Once SUBLOCADE is received, store SUBLOCADE according to regulatory and labeling requirements.
SUBLOCADE is a federal Class III controlled substance and requires special handling and storage.
Information on proper storage requirements can be found in the Prescribing Information for SUBLOCADE.
There may be other storage requirements not addressed in the Prescribing Information; refer to state and federal regulations.
Following administration of SUBLOCADE to the patient, submit a claim to the patient’s insurance provider. INSUPPORT can provide information on the buy‑and‑bill and claim submission processes.
Claims Submission
You may contact the patient's insurance provider to understand what portion of the medication cost should be collected from the patient. For patients enrolled in "Benefit Coverage Information" with INSUPPORT, INSUPPORT will provide a benefit summary to the healthcare provider (HCP) and the patient detailing the patient's estimated out-of-pocket responsibility for SUBLOCADE® (buprenorphine extended-release) injection, for subcutaneous use, CIII, as reported by the patient’s insurance provider, if applicable.
Following administration of SUBLOCADE to the patient, submit a claim to the patient's insurance provider. Here is billing and coding information.
If the claim is approved, the patient's insurance provider should provide payment to the HCP office.
For patients enrolled in the SUBLOCADE Copay Assistance Program, submit the paid claim and an itemized explanation of payments (EOP) from the insurance provider to INSUPPORT for the processing of the patient's copay assistance benefits.
Addressing claim denials
If your claim is denied by the patient's insurance provider, you will be notified of the denial reason by the insurance provider.
Some of the common reasons for denial include:
- Incomplete or inaccurate information
- Lack of prior authorization
- Diagnosis and procedure coding errors and omissions
- Insufficient medical necessity
For more information, please refer to the Terms and Conditions for the SUBLOCADE Copay Assistance Program for SUBLOCADE.
Additional Sites of Care
You may prefer patients receive SUBLOCADE at a facility other than your practice, while you continue to manage their overall care.
An Additional Site of Care (ASOC) is a facility or healthcare provider (HCP), other than the prescriber's office, that may provide a flexible option for the administration of SUBLOCADE injections.
Step 1
Step 2
Prescribe SUBLOCADE
For the selected location, download and complete the referral form or send a valid prescription and indicate the administration site. The administration site may require an order to inject.
Step 3
Coordinate Care
The patient care remains with the prescribing HCP to continue the determined addiction treatment modality.
Step 4
Refill Prescription
The pharmacy will refill SUBLOCADE when appropriate and will coordinate the next shipment with the administration site, prescribing HCP, and the patient.
The ASOC‑administering practitioner§ may also contact the patient directly to schedule subsequent injections.
§An ASOC‑administering practitioner (AP) is a Drug Enforcement Administration‑registered practitioner who is authorized to conduct the administration of controlled substances under local, state, and federal regulations.
If applicable, please see the SUBLOCADE Copay Assistance Program Terms and Conditions.
*The SUBLOCADE Copay Assistance Program is valid ONLY for patients with private insurance who are prescribed SUBLOCADE for on‑label use. Patients with government insurance are not eligible for the SUBLOCADE Copay Assistance Program, including, but not limited to, Medicare, Medicaid, Medigap, VA, DoD, TRICARE, CHAMPVA, or any other federally or state‑funded government‑assisted program. Other restrictions apply.
INDICATION
SUBLOCADE is for moderate to severe opioid use disorder in those who have initiated treatment with a dose of transmucosal buprenorphine or are being treated with buprenorphine and should include counseling and psychosocial support.
IMPORTANT SAFETY INFORMATION
WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; SUBLOCADE RISK EVALUATION AND MITIGATION STRATEGY
- Serious harm or death could result if administered intravenously. SUBLOCADE forms a solid mass upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo-embolic events, including life threatening pulmonary emboli, if administered intravenously.
- Because of the risk of serious harm or death that could result from intravenous self-administration, SUBLOCADE is only available through a restricted program called the SUBLOCADE REMS Program. Healthcare settings and pharmacies that order and dispense SUBLOCADE must be certified in this program and comply with the REMS requirements.
CONTRAINDICATIONS: SUBLOCADE should not be administered to patients who are hypersensitive to buprenorphine or any component of the delivery system.
WARNINGS AND PRECAUTIONS
Addiction, Abuse, and Misuse: SUBLOCADE contains buprenorphine, a Schedule III controlled substance that can be abused in a manner similar to other opioids. Buprenorphine is sought by people with opioid use disorder and is subject to criminal diversion. Monitor patients for conditions indicative of diversion or progression of opioid dependence and addictive behaviors.
Risk of Life-Threatening Respiratory Depression and Concomitant Use of Benzodiazepines or Other CNS Depressants with Buprenorphine: Buprenorphine has been associated with life-threatening respiratory depression, overdose, and death, particularly when misused by self-injection or with concomitant use of benzodiazepines or other CNS depressants (e.g., alcohol, non‑benzodiazepine sedative/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, gabapentinoids [gabapentin or pregabalin], and other opioids). Warn patients of the potential danger of self-administration of benzodiazepines, other CNS depressants, opioid analgesics, and alcohol while under treatment with SUBLOCADE. Counsel patients that such medications should not be used concomitantly unless supervised by a healthcare provider.
Use with caution in patients with compromised respiratory function (e.g., chronic obstructive pulmonary disease, cor pulmonale, decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression).
Opioids can cause sleep-related breathing disorders, e.g., central sleep apnea (CSA), sleep-related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion. Consider decreasing the opioid using best practices for opioid taper if CSA occurs.
Strongly consider recommending or prescribing an opioid overdose reversal agent (e.g., naloxone, nalmefene) at the time SUBLOCADE is initiated or renewed because patients being treated for opioid use disorder have the potential for relapse, putting them at risk for opioid overdose. Educate patients and caregivers on how to recognize respiratory depression and, if a reversal agent is recommended or prescribed, how to treat an opioid overdose. Emphasize the importance of calling 911 or getting emergency help, even if an opioid overdose reversal agent is administered.
Risk of Serious Injection Site Reactions: The most common injection site reactions are pain, erythema and pruritus with some involving abscess, ulceration, and necrosis. Some cases resulted in surgical depot removal, debridement, antibiotic administration, and SUBLOCADE discontinuation. The likelihood of serious injection site reactions may increase with inadvertent intramuscular or intradermal administration. Carefully review injection technique.
Neonatal Opioid Withdrawal Syndrome: Neonatal opioid withdrawal syndrome (NOWS) is an expected and treatable outcome of prolonged use of opioids during pregnancy. NOWS may be life-threatening if not recognized and treated in the neonate. Newborns should be observed for signs of NOWS and managed accordingly. Advise pregnant women receiving opioid addiction treatment with SUBLOCADE of the risk of neonatal opioid withdrawal syndrome.
Adrenal Insufficiency: Adrenal insufficiency has been reported with opioid use. If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. Wean the patient off the opioid.
Discontinuation of SUBLOCADE Treatment: Due to the long-acting nature of SUBLOCADE, if treatment is discontinued, monitor patients for several months for withdrawal and treat appropriately.
Inform patients that they may have detectable levels of buprenorphine for a prolonged period of time after treatment with SUBLOCADE. Considerations of drug-drug interactions, buprenorphine effects, and analgesia may continue to be relevant for several months after the last injection.
Risk of Hepatitis, Hepatic Events: Because cases of cytolytic hepatitis and hepatitis with jaundice have been observed in individuals receiving buprenorphine, monitor liver function tests prior to treatment and monthly during treatment.
Hypersensitivity Reactions: Hypersensitivity to buprenorphine-containing products have been reported most commonly as rashes, hives, and pruritus. Some cases of bronchospasm, angioneurotic edema, and anaphylactic shock have also been reported.
Precipitation of Opioid Withdrawal in Patients Dependent on Full Agonist Opioids: Buprenorphine may precipitate opioid withdrawal signs and symptoms in persons who are currently physically dependent on full opioid agonists if administered before the effects have subsided, at least 6 hours for short-acting opioids and 24 hours for long-acting opioids. Verify that patients have tolerated transmucosal buprenorphine before administering the first injection of SUBLOCADE.
Risks Associated With Treatment of Emergent Acute Pain: When patients need acute pain management, or may require anesthesia, treat patients receiving SUBLOCADE currently or within the last 6 months with a non-opioid analgesic whenever possible. If opioid therapy is required, patients may be treated with a high-affinity full opioid analgesic under the supervision of a physician, with particular attention to respiratory function, as higher doses may be required for analgesic effect and therefore, a higher potential for toxicity exists with opioid administration.
Advise patients of the importance of instructing their family members, in the event of emergency, to inform the treating healthcare provider or emergency room staff that the patient is physically dependent on an opioid and that the patient is being treated with SUBLOCADE.
Use in Opioid Naïve Patients: Because death has been reported for opioid naïve individuals who received buprenorphine sublingual tablet, SUBLOCADE is not appropriate for use in opioid naïve patients.
Use in Patients With Impaired Hepatic Function: Because buprenorphine levels cannot be rapidly decreased, SUBLOCADE is not recommended for patients with pre-existing moderate to severe hepatic impairment. Patients who develop moderate to severe hepatic impairment while being treated with SUBLOCADE should be monitored for several months for signs and symptoms of toxicity or overdose caused by increased levels of buprenorphine.
QTc Prolongation: QT studies with buprenorphine products have demonstrated QT prolongation ≤ 15 msec. Buprenorphine is unlikely to be pro-arrhythmic when used alone in patients without risk factors. The risk of combining buprenorphine with other QT-prolonging agents is not known. Consider these observations when prescribing SUBLOCADE to patients with risk factors such as hypokalemia, bradycardia, recent conversion from atrial fibrillation, congestive heart failure, digitalis therapy, baseline QT prolongation, subclinical long-QT syndrome, or severe hypomagnesemia.
Impairment of Ability to Drive or Operate Machinery: SUBLOCADE may impair the mental or physical abilities required for the performance of potentially dangerous tasks such as driving a car or operating machinery. Caution patients about driving or operating hazardous machinery until they are reasonably certain that SUBLOCADE does not adversely affect their ability to engage in such activities.
Orthostatic Hypotension: Buprenorphine may produce orthostatic hypotension.
Elevation of Cerebrospinal Fluid Pressure: Buprenorphine may elevate cerebrospinal fluid pressure and should be used with caution in patients with head injury, intracranial lesions, and other circumstances when cerebrospinal pressure may be increased. Buprenorphine can produce miosis and changes in the level of consciousness that may interfere with patient evaluation.
Elevation of Intracholedochal Pressure: Buprenorphine has been shown to increase intracholedochal pressure, as do other opioids, and thus should be administered with caution to patients with dysfunction of the biliary tract.
Effects in Acute Abdominal Conditions: Buprenorphine may obscure the diagnosis or clinical course of patients with acute abdominal conditions.
Unintentional Pediatric Exposure: Buprenorphine can cause severe, possibly fatal, respiratory depression in children who are accidentally exposed to it.
ADVERSE REACTIONS: Adverse reactions commonly associated with SUBLOCADE (≥5% of subjects) during clinical trials were constipation, headache, nausea, vomiting, increased hepatic enzymes, fatigue, and injection site pain and pruritus. This is not a complete list of potential adverse events. Please see the full Prescribing Information for a complete list.
DRUG INTERACTIONS
CYP3A4 Inhibitors and Inducers: Monitor patients starting or ending CYP3A4 inhibitors or inducers for potential over- or under-dosing.
Serotonergic Drugs: If concomitant use with serotonergic drugs is warranted, monitor for serotonin syndrome, particularly during treatment initiation, and during dose adjustment of the serotonergic drug.
Consult the full Prescribing Information for SUBLOCADE for more information on potentially significant drug interactions.
USE IN SPECIFIC POPULATIONS
Pregnancy: Opioid-dependent women on buprenorphine maintenance therapy may require additional analgesia during labor.
Lactation: Buprenorphine passes into the mother's milk. Advise breastfeeding women to monitor the infant for increased drowsiness and breathing difficulties.
Fertility: Chronic use of opioids may cause reduced fertility. It is not known whether these effects on fertility are reversible.
Geriatric Patients: Monitor geriatric patients receiving SUBLOCADE for sedation or respiratory depression.
To report a pregnancy or side effects associated with taking SUBLOCADE or any safety related information, product complaint, request for medical information, or product query, please contact PatientSafetyNA@indivior.com or 1-877-782-6966.
See full Prescribing Information, including Boxed Warning, and Medication Guide. For REMS information visit www.sublocadeREMS.com.
P-BAG-US-01881v2 Mar 2026